COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD
HC Q meta analysis
Source   PDF   Share   Tweet
See all 143 studies
PrEP, PEP, Early
Ladapo et al., medRxiv, doi:10.1101/2020.09.30.20204693 (Preprint) (meta analysis - not included in study count)
Randomized Controlled Trials of Early Ambulatory Hydroxych loroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis
Meta analysis of prophylactic and early treatment RCTs, 24% reduction in cases, hospitalization or death with HC Q, RR 0.76, p=0.025. No serious adverse cardiac events were reported. 5,577 patients.
The Boulware study provides a breakdown for treatment delay. For the case of < ~4 days (2 days enrollment, ~46 hours shipping), the result of the meta analysis becomes RR 0.68, p=0.0097.
The actual effect may be larger due to treatment delays, followup loss, protocol deviation, active placebos, no severity analysis for cases, and suboptimal regimens.
For the individual studies see [1, 2, 3, 4, 5].
combined cases/death/hospitalization, ↓24.0%, p=0.03
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.